Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in BMJ

Retrieve available abstracts of 34 articles:
HTML format
Text format



Single Articles


    January 2017
  1. MCCARTHY M
    Adverse events raise concerns over safety of new hepatitis C drugs.
    BMJ. 2017;356:j490.
    PubMed     Text format    


    December 2016
  2. OZIERANSKI P, King L
    Wales approves new hepatitis C drug while England deliberates.
    BMJ. 2016;355:i6499.
    PubMed     Text format    


    October 2016
  3. STAFFORD N
    Questions hang over European patent for hepatitis C drug after ruling.
    BMJ. 2016;355:i5493.
    PubMed     Text format    


  4. CATTANEO A, Maciocco G
    Compulsory licences for direct acting antiviral drugs for hepatitis C.
    BMJ. 2016;355:i5314.
    PubMed     Text format    


    August 2016
  5. KIESLICH K, Littlejohns P, Weale A
    Drug appraisal issues must be resolved at policy level.
    BMJ. 2016;354:i4519.
    PubMed     Text format    


  6. UZOIGWE CE, McCann J, Iacob G
    Patents: problem or panacea?
    BMJ. 2016;354:i4526.
    PubMed     Text format    


    July 2016
  7. ROY V, King L
    Betting on hepatitis C: how financial speculation in drug development influences access to medicines.
    BMJ. 2016;354:i3718.
    PubMed     Text format    


  8. MAZZUCATO M
    High cost of new drugs.
    BMJ. 2016;354:i4136.
    PubMed     Text format    


  9. GORNALL J, Hoey A, Ozieranski P
    A pill too hard to swallow: how the NHS is limiting access to high priced drugs.
    BMJ. 2016;354:i4117.
    PubMed     Text format    


    January 2016
  10. URRUTIA J, Porteny T, Daniels N
    What does it mean to put new hepatitis C drugs on a list of essential medicines?
    BMJ. 2016;353:i2035.
    PubMed     Text format    


  11. MCCARTHY M
    US hepatitis C virus testing recommendations may miss 25% of cases, study finds.
    BMJ. 2016;353:i2337.
    PubMed     Text format    


  12. MCPHERSON S, Lucey MR, Moriarty KJ
    Decompensated alcohol related liver disease: acute management.
    BMJ. 2016;352:i124.
    PubMed     Text format    


  13. WISE J
    Newer tests for hepatitis C virus could transform screening.
    BMJ. 2016;353:i3420.
    PubMed     Text format    


  14. MAYOR S
    Curative hepatitis C treatment is effective in drug users, trial shows.
    BMJ. 2016;354:i4346.
    PubMed     Text format    


  15. HANCOX SH, Howlett DC
    Acute hepatitis in a teenager.
    BMJ. 2016;354:i3997.
    PubMed     Text format    


  16. DYER C
    Patient threatens legal action over lack of compensation for hepatitis C contaminated blood.
    BMJ. 2016;354:i4937.
    PubMed     Text format    


    January 2015
  17. KORETZ RL, Lin KW, Ioannidis JP, Lenzer J, et al
    Authors' reply to Selvapatt and colleagues, Matthews and colleagues, Badrinath, and Ward and Lee.
    BMJ. 2015;350:h674.
    PubMed     Text format    


  18. KORETZ RL, Lin KW, Ioannidis JP, Lenzer J, et al
    Authors' reply to Foster and colleagues.
    BMJ. 2015;350:h1000.
    PubMed     Text format    


  19. BAGCCHI S
    Campaigners challenge patent applications for hepatitis C drug in five countries.
    BMJ. 2015;350:h2938.
    PubMed     Text format    


  20. WISE J
    UK government apologises for contaminated blood scandal.
    BMJ. 2015;350:h1673.
    PubMed     Text format    


  21. KMIETOWICZ Z
    Thousands of patients in England to get new hepatitis C drugs.
    BMJ. 2015;350:h3222.
    PubMed     Text format    



  22. Experts disagree over necessity of hepatitis E vaccine in Nepal.
    BMJ. 2015;350:h3463.
    PubMed     Text format    


  23. BRUNETTO MR, De Luca A, Messori A, Zignego AL, et al
    Reducing the price of new hepatitis C drugs in the Tuscany region of Italy.
    BMJ. 2015;350:h3363.
    PubMed     Text format    


  24. KMIETOWICZ Z
    China rejects patent on hepatitis C drug sofosbuvir.
    BMJ. 2015;350:h3429.
    PubMed     Text format    


  25. COUSINS S
    Experts disagree over necessity of hepatitis E vaccine in Nepal.
    BMJ. 2015;350:h3393.
    PubMed     Text format    


  26. MCCARTHY M
    Lawsuit seeks access to data from hepatitis C drug trial.
    BMJ. 2015;350:h3564.
    PubMed     Text format    


  27. TRAVASSO C
    Viral hepatitis surveillance and outbreak report is published in India.
    BMJ. 2015;351:h4372.
    PubMed     Text format    


  28. RIDDELL A, Kennedy I, Tong CY
    Management of sharps injuries in the healthcare setting.
    BMJ. 2015;351:h3733.
    PubMed     Text format    


  29. HAWKES N
    NICE approval of new hepatitis drug could result in pound700m bill for NHS.
    BMJ. 2015;351:h5554.
    PubMed     Text format    


  30. SUNDARAM V, Kowdley K
    Management of chronic hepatitis B infection.
    BMJ. 2015;351:h4263.
    PubMed     Text format     Abstract available


  31. DE SCHRYVER AA, Van Hooste W, Van Acker H, Claessens B, et al
    Managing risk of hepatitis B after sharps injuries.
    BMJ. 2015;351:h5568.
    PubMed     Text format    


  32. MCCARTHY M
    Hepatitis C drug maker puts profit ahead of patients, US Senate report charges.
    BMJ. 2015;351:h6573.
    PubMed     Text format    


  33. TONG CY, Riddell A, Kennedy I
    Authors' reply to De Schryver and colleagues.
    BMJ. 2015;351:h5573.
    PubMed     Text format    


  34. OSOWICKI J, Curtis N
    Sharps injuries in the community: lower risk than in healthcare settings.
    BMJ. 2015;351:h4766.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: